Pharmaron Risk Report

⚖️ Legal & Regulatory

Pharmaron has encountered several legal and regulatory challenges that could impact its reputation and operations. Concerns over compliance arise from reports of NIH and the Department of Defense collaborating with Chinese labs on controversial experiments.

• GOP and a watchdog allege that the Department of Defense and NIH are collaborating on controversial dog experiments with Chinese labs 🗓 April 28, 2025.
• NIH decided not to renew drug experiments on beagle puppies, raising ethical concerns 🗓 May 29, 2025.
• Secretary of Defense Lloyd Austin was reportedly involved in shielding biotech firms during a gain-of-function research audit, as per a GOP senator claim 🗓 June 26, 2024.

📜 Innovation & R&D

Pharmaron shows significant progress in its R&D activities, focusing on expanding its capabilities and global reach. The recent partnership with CN Bio highlights its move toward advanced drug discovery technologies.

• Pharmaron and CN Bio announced a strategic partnership to develop organ-on-a-chip technology for a global R&D platform 🗓 April 23, 2025.
• The company has entered into a partnership with CN Bio to expand their organ-on-a-chip capabilities 🗓 April 23, 2025.
• Pharmaron received a UK grant to expand its cell and gene facility acquired from AbbVie 🗓 March 29, 2023.

🏅 Awards & Recognition

This category currently has no significant events or changes to report.